mTOR(Ab-2481) Antibody

Catalog No: #21515

Package Size: #21515-1 50ul #21515-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


Host SpeciesRabbitClonalityPolyclonalPurificationAntibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.ApplicationsIHCSpecies ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479-2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Description	
ClonalityPolyclonalPurificationAntibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.ApplicationsIHCSpecies ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479-2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Product Name	mTOR(Ab-2481) Antibody
PurificationAntibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.ApplicationsIHCSpecies ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479-2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCI, 0.02% sodium azide and 50% glycerol.	Host Species	Rabbit
purified by affinity-chromatography using epitope-specific peptide.ApplicationsIHCSpecies ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479-2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Clonality	Polyclonal
ApplicationsIHCSpecies ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Purification	Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were
Species ReactivityHu Ms RtSpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.		purified by affinity-chromatography using epitope-specific peptide.
SpecificityThe antibody detects endogenous level of total mTOR protein.Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCI, 0.02% sodium azide and 50% glycerol.	Applications	IHC
Immunogen TypePeptide-KLHImmunogen DescriptionPeptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Species Reactivity	Hu Ms Rt
Immunogen DescriptionPeptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Specificity	The antibody detects endogenous level of total mTOR protein.
Target NamemTOROther NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Immunogen Type	Peptide-KLH
Other NamesFRAP; FRAP1; FRAP2; RAFT1; Rapamycin target proteinAccession No.Swiss-Prot: P42345NCBI Protein: NP_004949.1UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Immunogen Description	Peptide sequence around aa.2479~2483 (I-H-S-F-I) derived from Human mTOR.
Accession No. Swiss-Prot: P42345NCBI Protein: NP_004949.1 Uniprot P42345 GeneID 2475; Concentration 1.0mg/ml Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Target Name	mTOR
UniprotP42345GeneID2475;Concentration1.0mg/mlFormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Other Names	FRAP; FRAP1; FRAP2; RAFT1; Rapamycin target protein
GeneID 2475; Concentration 1.0mg/ml Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Accession No.	Swiss-Prot: P42345NCBI Protein: NP_004949.1
Concentration 1.0mg/ml Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	Uniprot	P42345
Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.	GeneID	2475;
sodium azide and 50% glycerol.	Concentration	1.0mg/ml
	Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02%
Storage Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.		sodium azide and 50% glycerol.
	Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details

Predicted MW: 289kd

Immunohistochemistry: 1:50~1:100

Images



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using mTOR(Ab-2481) Antibody #21515(left) or the same antibody preincubated with blocking peptide(right). Kinase subunit of both mTORC1 and mTORC2, which regulate cell growth and survival in response to nutrient and hormonal signals. mTORC1 is activated in response to growth factors or amino-acids. Amino-acid-signaling to mTORC1 is mediated by Rag GTPases, which cause amino-acid-induced relocalization of mTOR within the endomembrane system. Growth factor-stimulated mTORC1 activation involves AKT1-mediated phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB GTPase that potently activates the protein kinase activity of mTORC1. Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. mTORC1 phosphorylates EIF4EBP1 and releases it from inhibiting the elongation initiation factor 4E (eiF4E). mTORC1 phosphorylates and activates S6K1 at 'Thr-421', which then promotes protein synthesis by phosphorylating PDCD4 and targeting it for degradation. mTORC2 is also activated by growth factors, but seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'.

Sabers, C.J. et al. (1995) J. Biol. Chem. 270, 815-822. Brown, E.J. et al. (1994) Nature 369, 756-758. Dennis, P.B. et al. (2001) Science 294, 1102-1105. Sabatini, D.M. et al. (1994) Cell 78, 35-43.

Note: This product is for in vitro research use only